Results 41 to 50 of about 362,065 (266)
Background and Objectives: Diphtheria is a potentially fatal disease caused by toxigenic bacterial infection, particularly from Corynebacterium diphtheriae (C. diphtheriae). Isolation of C.
Yeva Rosana +4 more
doaj +1 more source
Identification of a diphtheria toxin‐like gene family beyond the Corynebacterium genus
Diphtheria toxin (DT), produced by Corynebacterium diphtheria, is the causative agent of diphtheria and one of the most potent protein toxins known; however, it has an unclear evolutionary history.
Michael J. Mansfield +3 more
semanticscholar +1 more source
Imported Toxin-Producing Cutaneous Diphtheria — Minnesota, Washington, and New Mexico, 2015–2018
From September 2015 to March 2018, CDC confirmed four cases of cutaneous diphtheria caused by toxin-producing Corynebacterium diphtheriae in patients from Minnesota (two), Washington (one), and New Mexico (one).
J. Griffith +10 more
semanticscholar +1 more source
Background Infections caused by Corynebacterium ulcerans, a zoonotic pathogen, have been reported worldwide. This microorganism is known to produce the diphtheria toxin and cause diphtheria‐like illness.
Koji Wake +10 more
doaj +1 more source
Diphtheria Toxin-Induced Cell Death Triggers Wnt-Dependent Hair Cell Regeneration in Neonatal Mice
Cochlear hair cells (HCs), the sensory cells that respond to sound, do not regenerate after damage in adult mammals, and their loss is a major cause of deafness.
Lingxiang Hu +5 more
semanticscholar +1 more source
Diphtheria toxin-mediated ablation of lymphatic endothelial cells results in progressive lymphedema.
Development of novel treatments for lymphedema has been limited by the fact that the pathophysiology of this disease is poorly understood. It remains unknown, for example, why limb swelling resulting from surgical injury resolves initially, but recurs in
J. Gardenier +11 more
semanticscholar +1 more source
Background: Targeted cancer therapies have played a great role in the treatment of malignant tumors, in the recent years. Among these therapies, targeted toxin therapies such as immunotoxins, has improved the patient’s survival rate by minimizing the ...
Sahel Amoozadeh +4 more
doaj +1 more source
Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development
Background: Targeted toxins require multiple treatments and therefore must be deimmunized. We report a method of protein deimmunization based on the point mutation of highly hydrophilic R, K, D, E, and Q amino acids on the molecular surface of truncated ...
J. Schmohl +3 more
semanticscholar +1 more source
TRPA1+αCGRP+ sensory neurons in the nodose ganglion detect external insults such as lipopolysaccharide (LPS) and interact directly with pulmonary neuroendocrine cells (PNECs), promoting their activation and proliferation. This neural‐epithelial interaction amplifies lung inflammation.
Jie Chen +16 more
wiley +1 more source
The cholix toxin gene (chxA) was first identified in V. cholerae strains in 2007, and the protein was identified by bioinformatics analysis in 2008. It was identified as the third member of the diphtheria toxin group of mono-ADP-ribosyltransferase toxins
Miguel R. Lugo, A. Rod Merrill
doaj +1 more source

